Item 1.01 Entry into a Material Definitive Agreement · On July 5, 2012, West Pharmaceutical Services, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with a group of institutional investors (the “Purchasers”) pursuant to which the Purchasers purchased $42,000,000 3.67% Series A Senior Notes due July 5, 2022 (“Series A Notes”), $53,000,000 3.82% Series B Senior Notes due July 5, 2024 (“Series B Notes”) and $73,000,000 4.02% Series C Senior Notes due July 5, 2027 (“Series C Notes ...
Manager Commentary (unaudited), 1 ; Financial Data and Fund Performance, ; Apollo Senior Floating Rate Fund Inc. (unaudited), 3 ; Apollo Tactical Income Fund Inc. (unaudited), 5
o, Preliminary Proxy Statement ; o, Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ; x, Definitive Proxy Statement ; o, Definitive Additional Materials
UNITED STATES · SECURITIES AND EXCHANGE COMMISSION · Washington, DC 20549 · PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE · SECURITIES EXCHANGE ACT OF 1934 · (Amendment No. )
UNITED STATES · SECURITIES AND EXCHANGE COMMISSION · Washington, D.C. 20549 · INFORMATION REQUIRED IN PROXY STATEMENT · SCHEDULE 14A INFORMATION · Proxy Statement Pursuant to Section 14(a) of the · Securities Exchange Act of 1934 · Filed by the Registrant ☒ · Filed by a Party other than the Registrant ☐ · Check the appropriate box:
UNITED STATES · SECURITIES AND EXCHANGE COMMISSION · Washington, D.C. 20549 · Investment Company Act file number 811-22481 · (Exact name of registrant as specified in charter) · 9 West 57th Street · (Address of principal executive offices) (Zip code) · James Vanek, President · 9 West 57th Street · (Name and address of agent for service) · Registrant’s telephone number, including area code: (212) 515-3200 · Date of fiscal year end: December 31 · Date of reporting period: December 31, 2023
, Page ; Part I. Financial Information:, 3 ; Item 1. Financial Statements, 3 ; Condensed Consolidated Balance Sheets,
General Information, 1 ; Proposal 1. Election of JBS Directors, 8 ; Proposal 2. Election of Equity Directors, 10 ; Proposal 3. Advisory Vote on Executive Compensation, 12
UNITED STATES · SECURITIES AND EXCHANGE COMMISSION · Washington, D.C. 20549 · SCHEDULE 14A · Proxy Statement Pursuant to Section 14(a) of the Securities · Exchange Act of 1934 (Amendment No. ) · Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ · Check the appropriate box:
PROXY STATEMENT, 1 ; PROPOSAL 1 - ELECTION OF DIRECTORS, 4 ; CORPORATE GOVERNANCE, 8 ; CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS, 17